GSK’s Juluca gets European Medicines Agency approval for HIV therapy

Date: 2018-03-24   Author: Saipriya Iyer  Category: #news

GSK’s Juluca gets European Medicines Agency approval for HIV therapy

European Medicines Agency, an EU authority that evaluates medicinal products, has approved GlaxoSmithKline’s two-drug treatment for HIV (human immunodeficiency virus), that causes AIDS (Acquired Immune Deficiency Syndrome). Reportedly, the board constituted for evaluating the human use of medicinal product supported the application of the two-drug regimen.

Juluca, a new HIV drug therapy, is a fixed dosage tablet combining two previously approved medicines, rilpivirine & dolutegravir, and is available for the patients on a stable drug treatment for nearly half of the year.

As per reliable reports, Juluca has been produced by GSK’s subsidiary ViiV Healthcare, which has a small stake owned by Shionogi and Pfizer. ViiV’s integrase inhibitor medicine dolutegravir is a part of GSK’s old triple-drug treatment that is used to control the spread of HIV in the human body.

Earlier, in the last quarter of 2017, U.S Food and Drug Administration (FDA) had approved the two-drug regimen of GSK. The CHMP (Committee for Medicinal Products for Human Use) approval is likely to facilitate Juluca’s approval by the European Commission, which is expected to come by the second quarter of this year. 

According to U.S. FDA, Juluca’s safety & efficiency in the adult HIV patients were assessed in two clinical tests in which 1,024 patients, whose HIV was suppressed due to the existing anti-HIV drug therapy, participated. Some of the patients were asked to either continue with the anti-HIV drug treatment or switch to Juluca’s two-drug therapy.

Reportedly, FDA derived the outcomes from the clinical trials on both the patients treated with GSK’s Juluca drug as well as the ones receiving anti-drug treatment. The regulator found that GSK’s two drug therapy had proved more effective in treating the HIV virus in the patients as compared to those who were treated with anti-HIV medicines.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

3D Visualization System Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2027

Author: Ashwin Naphade

The and United States 3D Visualization System Market Forecast Report provides details analysis of and United States 3D Visualization System industry which will accelerate your business. and United States 3D Visualization System market report cover...


3D Systems Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2027

Author: Ashwin Naphade

and China 3D Systems Market Trends covers the companies’ data including Growth potential analysis, Industry segmentation, Business trends, Growth drivers, Price trend analysis. The Report also Gives Detail Analysis on Market concern Like an...


Cinema Ticketing System Service Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2027

Author: Ashwin Naphade

and United States Cinema Ticketing System Service Market report provides key statistics on the market status of the and United States Cinema Ticketing System Service Industry and is a valuable source of guidance and direction for companies and in...